<DOC>
	<DOCNO>NCT00002157</DOCNO>
	<brief_summary>To allow patient HIV-associated waste receive thalidomide treatment 1 2 dos . To gain safety efficacy data broad base patient HIV-associated waste order support Celgene 's pivotal placebo-controlled study .</brief_summary>
	<brief_title>Compassionate Use Study Two Dose Levels Thalidomide Adults With HIV Wasting Syndrome</brief_title>
	<detailed_description>Patients randomize receive thalidomide 1 2 dos 12 week initially , response assess week 2 , 4 , 8 , 12 . Patients fail low dose eligible increase dose high dose . Treatment may continue indefinitely . After 12 week , patient continue treatment evaluate every 2 month 6 additional month , every 6 month thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Wasting Syndrome</mesh_term>
	<mesh_term>HIV Wasting Syndrome</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy . Prophylaxis treatment opportunistic infection . Patients must : HIVassociated wasting . Prior Medication : Allowed : Prior enrollment Celgene 's placebocontrolled thalidomide study , provide patient meet specify criterion continue study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1998</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Thalidomide</keyword>
</DOC>